We are excited to report that we have terminated today the development of the core functionalities for a software for surgical guidance of Radio Frequency (RF) ablation of liver tumors. The software will be used intraoperatively and support physicians in better targeting the tissues that they need to necrotize during the procedure, ensuring that all the malignant tissues are treated and reducing chances of recurrence of the tumor.

These developments have been supported by SBIR Phase I (1R43CA189515-01) and Phase II (2R44CA189515-02A1) grants from the National Cancer Institute. We are planning a clinical trial which will be conducted by collaborating physicians at the Dartmouth Hitchcock Medical Center.